AMENDMENTS TO THE CLAIMS

Please enter the following amendments to the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

1. (Currently Amended) A lipophilic formulation for nasal application comprising:

a) at least one sexual hormone drug in an amount [[from]] of between 0.5% to 6.0% by weight of the formulation;

b) at least one lipophilic or partly lipophilic carrier, comprising at least one oil in an amount of between ~~60% and 98%~~ 85% and 95% by weight of the formulation; [[and]]

c) a compound or a mixture of compounds having a surface tension decreasing activity in an amount effective for *in situ* generation of an emulsion upon contact of the formulation with water; and

d) a viscosity regulating agent,

wherein no water is added to the formulation.

2. (Original) The formulation according to claim 1, wherein the lipophilic carrier comprises an oil.

3. (Previously Presented) The formulation according to claim 2, wherein said oil is vegetable oil.

4. (Original) The formulation according to claim 3, wherein said oil is castor oil.

5. (Currently Amended) The formulation according to claim [[2]]1, wherein the amount of the at least one oil ~~comprises between 75% and 95%~~ is in an amount of around 90% by weight of the formulation.

6. (Currently Amended) The formulation according to claim 1, wherein component (c) comprises at least one surfactant selected from the croup consisting of lecithin, fatty acid ester of polyvalent alcohols, of sorbitanes, of polyoxyethylensorbitans, of polyoxyethylene, of sucrose, of polyglycerol ~~and/or~~ and at least one humectant selected from the group consisting of sorbitol, glycerine, polyethylene glycol, [[and]] macrogol glycerol, [[or]] and a mixture thereof.

7. (Original) The formulation according to claim 6, wherein component (c)

comprises an oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides.

8. (Currently Amended) The formulation according to claim [[6]]1, wherein component (c) ~~is comprised within the formulation in an amount of from 1 to 20% by weight~~ is in an amount of between 1% and 5% by weight of the formulation.

9. (Canceled)

10. (Currently Amended) The formulation according to claim [[9]]1, wherein said viscosity regulating agent comprises a thickener or gelling agent selected from the group consisting of cellulose and cellulose derivatives, polysaccharides, carbomers, polyvinyl alcohol, povidone, colloidal silicon dioxide, cetyl alcohols, stearic acid, beeswax, petrolatum, triglycerides and lanolin, [[or]]and a mixture thereof.

11. (Previously Presented) The formulation according to claim 10, wherein said viscosity regulating agent is colloidal silicon dioxide.

12. (Currently Amended) The formulation according to claim [[9]]1, wherein the viscosity regulating agent is ~~comprised within the formulation~~ in an amount of between 1% and 3% ~~from 0.5 to 10%~~ by weight of the formulation.

13. (Previously Presented) The formulation according to claim 1, wherein the sexual hormone drug is testosterone.

14-19. (Canceled)

20. (Currently Amended) The formulation [[of]]according to claim 1, wherein the sexual hormone drug is ~~comprised within the formulation~~ in an amount of between 2% and 4% by weight of the formulation ~~from 2 to 4% by weight~~.

21. (Currently Amended) The formulation [[of]]according to claim 1, wherein the sexual hormone drug is ~~comprised within the formulation~~ in an amount of 2% by weight of the formulation ~~from 0.5 to 2% by weight~~.

22. (New) A lipophilic formulation for nasal application comprising:

a) at least one sexual hormone drug in an amount of 2 % by weight of the formulation;

b) at least one lipohilic or partly lipophilic carrier, comprising at least one oil in an amount of 90% by weight of the formulation;

c) a compound or a mixture of compounds having a surface tension decreasing activity in an amount effective for *in situ* generation of an emulsion upon

contact of the formulation with water in an amount of 4% by weight of the formulation; and

d) a viscosity regulating agent in an amount of 3% by weight of the formulation,

wherein no water is added to the formulation.

23. (New) The formulation according to claims 1 or 22, wherein after a single application of the formulation, the level of unbound sexual hormone drug is constant over at least 6 to 10 hours, mimicking the physiologic daily rhythm of testosterone release.

24. (New) The formulation according to claims 1 or 22, wherein after a single application of the formulation, the level of unbound sexual hormone drug is constant over at least 10 hours, mimicking the physiologic daily rhythm of testosterone release.